Research Article

Antidepressant-Like Effects and Cognitive Enhancement of Coadministration of Chaihu Shugan San and Fluoxetine: Dependent on the BDNF-ERK-CREB Signaling Pathway in the Hippocampus and Frontal Cortex

Lijing Yan, Xia Xu, Zhenyu He, Sheng Wang, Linlin Zhao, Juan Qiu, Dongsheng Wang, Zhicheng Gong, Xinjian Qiu, and Huiyong Huang

1Laboratory of Ethnopharmacology, Institute of Integrated Traditional Chinese and Western Medicine, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China
2Taizhou Hospital of Integrated Traditional Chinese and Western Medicine, Taizhou, Zhejiang 317500, China
3The Second Clinical Medical College, Zhejiang Chinese Medicine University, Hangzhou, Zhejiang 310053, China
4Department of Health Management, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013, China
5Department of Nuclear Medicine, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410008, China
6Department of Pharmacy, Institute for Rational and Safe Medication Practices, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China
7Institute of Traditional Chinese Medicine Diagnosis, Hunan University of Traditional Chinese Medicine, Changsha, Hunan 410208, China

Correspondence should be addressed to Xinjian Qiu; qiuxjxy@csu.edu.cn and Huiyong Huang; huanghy68@126.com

Lijing Yan and Xia Xu contributed equally to this work.

Received 24 July 2019; Revised 8 December 2019; Accepted 4 January 2020; Published 25 February 2020

Academic Editor: Nicola Simola

Copyright © 2020 Lijing Yan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Fluoxetine (FLU) is the first-line and widely used medication for depression; however, FLU treatment is almost ineffective in 30%-40% of patients with depression. In addition, there are some problems in FLU treatment, such as delayed efficacy, large side effects, and poor tolerance. Chaihu Shugan San (CSS) is a classic and effective antidepressant Chinese herbal medicine that has been used in China for thousands of years. CSS or coadministration of CSS and FLU has become one of the most recommended methods in the treatment of depression in China. However, the specific pathways of CSS and coadministration of CSS and FLU for antidepressant are still unclear. Objective. This study was designed to evaluate the antidepressant effects of CSS and coadministration of CSS and FLU. Methods. The chronic unpredictable mild stress (CUMS) rat model was used to simulate depression. 120 healthy adult male Sprague-Dawley (SD) rats were randomly divided into seven groups: the control group, CUMS group, low-dose CSS group, high-dose CSS group, FLU group, coadministration of low-dose CSS and FLU group, and coadministration of high-dose CSS and FLU group. The rats in different groups were given different interventions. Then, the depression-like behavior and cognitive function were evaluated by the sucrose preference test (SPT), forced swimming test (FST), open field test (OFT), and Y-maze test. What is more, the antidepressant mechanism of CSS and coadministration of CSS and FLU were studied through BDNF mRNA, ERK mRNA, CREB mRNA, BDNF, p-ERK/ERK, and p-CREB/CREB levels in the hippocampus and frontal cortex by Western blot and RT-PCR. Results. Compared with the CUMS group, CSS and coadministration of CSS and FLU could alleviate the depressive symptoms and improve cognitive function in CUMS rats (p < 0.05); CSS and
coadministration of CSS and FLU could increase the expression of BDNF, p-CREB/CREB, p-ERK/ERK, and BDNF mRNA, CREB mRNA, and ERK mRNA in the hippocampus and frontal cortex ($p < 0.05$). Besides, the high-dose CSS combined with the fluoxetine group was significantly better than the fluoxetine group and CSS group ($p < 0.05$). Discussion and Conclusion. Finally, we found that both CSS and coadministration of CSS and FLU play an antidepressant role, which may be due to the regulation of the BDNF/ERK/CREB signaling pathway in the hippocampus and frontal cortex. Among them, the coadministration of CSS and FLU can enhance the antidepressant effect of CSS or FLU alone, and the underlying mechanism needs further investigation.

1. Introduction

Depression is a mood disorder characterized by persistent feeling of sadness, loss of interest, decline in thinking and cognitive function, and disorder of physiological function [1, 2]. The WHO reported that it could be the third principal cause of disability worldwide by 2020 [3]. In addition, depression can easily lead to suicide and decreased fertility [4–6]. Based on data from the 2012 China Family Panel Studies survey, studies have shown that mental illness contributes to 14.7% of total personal expected medical spending in China, respectively, with depression and depressive symptoms accounting for 6.9% and 7.8% [7]. Therefore, it is not difficult to conclude that depression is a major neurological disease that seriously threatens human health and quality of life. Depression causes a serious burden to the society, and there is an urgent need for safe and effective treatment [8].

At present, common antidepressants mainly include tricyclic antidepressants and selective serotonin (5-HT) reuptake inhibitors. However, tricyclic antidepressants have adverse effects on the liver, kidneys, and heart according to the related report [9]. Fluoxetine, a selective serotonin (5-HT) reuptake inhibitor, is the first-line and widely used medication for depression; however, fluoxetine treatment is almost ineffective in 30%–40% of patients with depression. In addition, the treatment with fluoxetine has some problems such as delayed effect, large side effects, and poor tolerance [10, 11]. For example, it can cause severe side effects such as fatigue, headache, loss of appetite, weight gain, nausea, and bad mood [12]. Objective or subjective serious side effects usually force some patients to abandon medication [13]. Considering the possible harm, the lack of effective and safe treatments worldwide, and the high incidence of depression, more effective and safe antidepressants are urgently needed. Phytochemicals and medicinal herbs could be a dependable alternative antidepressant for those patients who do not obtain benefit from conventional antidepressant [14].

It is estimated that up to 80% of the population in developing countries use traditional herbs for primary health care [15]. CSS or coadministration of CSS and FLU is commonly used to enhance antidepressant effect and reduce side effects in Chinese clinics [16], which was confirmed by multiple studies [17–19]. Chaihu Shugan San (CSS) is a classic and effective antidepressant Chinese herbal medicine that has been used in China for thousands of years. CSS or coadministration of CSS and FLU has become one of the most recommended methods for the treatment of depression in China.

CSS consists of seven Chinese herbs, i.e., the root of Bupleurum chinense DC. (Chai-hu), the root of Paeonia lactiflora Pall. (Bai-shao), the pericarp of Citrus reticulata Blanco (Chuan-pi), the root of Ligusticum chuanxiong Hort. (Chuan-xiong), the root of Cyperus rotundus L. (Xiang-fu), the fruit of Citrus aurantium L. (Zhi-qiao), and the root of Glycyrrhiza uralensis Fisch. (Gan-cao) [20, 21]. Our previous study found that chronic unpredictable mild stress (CUMS) affects neuroendocrine, behavior, and related molecular expression and ultimately leads to depression in rats. CSS can regulate the behavior of CUMS rats by regulating JNK and ERK1/2 mRNA expression in the hippocampus [22–24]. Related reports have found that CSS can significantly improve the depression status of model rats, and its mechanism may be related to the increase of mRNA expression of BDNF and TrkB in the hippocampus, amygdala, and frontal lobe [25].

Fluoxetine can increase the occurrence of hippocampal neurons in rats with depression, improve the stereology of synaptic structures, and restore the structure and function of the hippocampus [26]. Fluoxetine can reduce the expression of Bax mRNA in the hippocampus of rats with depression, increase the expression of Bcl-2 mRNA, and reduce neuronal apoptosis [27]. In summary, neuronal regeneration and apoptosis, neuroplasticity, BDNF, and related pathway regulation may be a common mechanism of antidepressants such as CSS and fluoxetine.

The combination of CSS and fluoxetine can effectively alleviate the symptoms of patients with depression. However, the potential neuroprotective effects and mechanisms of CSS and fluoxetine on CUMS-induced depression remain to be elucidated. Therefore, in this study, we used the CUMS model to study the antidepressant-like effects and cognitive enhancement of coadministration of CSS and fluoxetine. In addition, BDNF mRNA, ERK mRNA, CREB mRNA, BDNF, p-ERK/ERK, and p-CREB/CREB levels in the hippocampus and frontal cortex were measured to explain the possible mechanism of CSS and fluoxetine.

2. Materials and Methods

2.1. Experimental Animals. 120 male clean healthy adult SD rats (body weight 200 ± 20 g) were provided by the Animal Experimental Center of Central South University (Hunan, China), and the experimental animal license number was SYXX (Xiang) 2016-0301. The mice were housed individually, lit at 07:00 am, then given light on a schedule of 12-hour light and 12-hour dark followed. The feeding space is maintained at an ambient temperature of 23–25°C and a relative humidity of 54%–66%. Throughout the experiment, animals were given food and water unless otherwise stated. All procedures were approved and implemented in accordance with the guidelines of the ethics of Xiangya Hospital in Central South University.
2.2. CSS. The CSS formula used in this experiment is based on our previous research [13]. All Chinese medicines were purchased by the Chinese Pharmacy of Xiangya Hospital and identified by the Associate Professor Lei Peng in compliance with the Pharmacopoeia requirements. The origin, batch number, and ratio of the herb medicine are displayed in Table 1.

2.3. Drugs and Reagents. 20 mg/granules fluoxetine hydrochloride capsules were purchased from Lilly Suzhou Pharmaceutical Co., Ltd. Rabbit anti-mouse ERK1/2 antibody was purchased from the American Abcam company. Rabbit anti-mouse BDNF antibody was purchased from Abcam, USA. The DNA marker was purchased from Beijing Dingguo Biotechnology Company. DNA marker was purchased from the Invitrogen company. Chloroform, isopropanol, and absolute ethanol were of analytical grade and purchased from Shanghai Chemical Reagent Company. The BCA protein quantification kit was purchased from VECTORS Bio GmbH, USA. The SABC kit was purchased from VECTOR Bio GmbH, USA. The streptavidin–biotin–horseradish peroxidase complex was purchased from VECTOR Bio GmbH, USA. The streptavidin–biotin–horseradish peroxidase complex was purchased from VECTOR Bio GmbH, USA. The streptavidin–biotin–horseradish peroxidase complex was purchased from VECTOR Bio GmbH, USA. The streptavidin–biotin–horseradish peroxidase complex was purchased from VECTOR Bio GmbH, USA.

2.4. Preparation of CSS Extract. The original herbal ingredients of CSS were mixed and crushed into small pieces in a ratio of 4:4:3:3:3:3:1. The compound was immersed in water (1:8, w/v) for 30 minutes at room temperature, then heated to boiling, and boiled for a further 0.5 hours. The filtrate was collected, and the residue was refluxed in the same volume of water and heated for a further 0.5 hours. The filtrate was collected, and the residue was refluxed in the same volume of water and heated for a further 0.5 hours. The two filtrates were combined and concentrated in vacuo to give a CSS extract of 2.1 g/mL. When used, it is made into a certain concentration with distilled water as needed [11].

2.5. Drug Administration. To study the antidepressant effects of CSS and fluoxetine, rats were randomly divided into the following 7 groups (n = 15) using a random number table: control group (saline), model group (saline), low-dose CSS group (CSS 5.9 g/(kg·d)), high-dose CSS group (CSS 11.8 g/(kg·d)), fluoxetine group (FLU 1.8 g/(kg·d)), coadministration of low-dose CSS and FLU group (CSS 5.9 g/(kg·d)+FLU 1.8 g/(kg·d)), coadministration of high-dose CSS and FLU group (CSS 11.8 g/(kg·d)+FLU 1.8 g/(kg·d)). The chronic unpredictable mild stress (CUMS) rat model was used to simulate depression. Except the control group, the other six groups received unpredictable mild stress for 28 days to simulate depression. The rats in different groups were given different interventions for 4 weeks. The combination groups were given fluoxetine one hour after the administration of CSS. Behavioral tests were performed before and after the administration.

2.6. CUMS Procedure. We established chronic depression models with chronic unpredictable mild stress. CUMS includes exposure to various unpredictable stress factors (random), including fasting (24 h), 4°C cold water swimming (5 min), tail (1 min), 45°C hot water swimming (5 min), restraint (3 h), shaking (60 times/min, 10 min), and moist litter (24 h).

A total of 7 kinds of stimulation methods were randomly stimulated in 28 days to stimulate the rats. In order to avoid the rats being accustomed to the same kind of stimulation, the same stimulation was not performed for two consecutive days. All pressures were applied individually and continuously during the day and night, and each stimulus was used 2-3 times cumulatively. Rats in the control group remained undisturbed at all times, except for necessary procedures such as routine cage cleaning.

2.7. Behavioral Testing

2.7.1. Sucrose Preference Test (SPT). Rats were trained for 72 hours before the start of the experiment. The first 24 hours gave rats 2 bottles of 1% syrup, and the second 24 hours gave rats 1% syrup and 1 bottle of pure water. The third 24 hours deprived rats of food and water. Then, a total of 2 bottles of syrup and pure water (100 mL each) were administered to each rat, and the consumption of 1% syrup and pure water was measured for 1 hour to calculate the saccharide consumption rate: sugar consumption rate = sugar water consumption/sugar water + pure water consumption.

2.7.2. Open Field Test (OFT). Using a 100 cm × 100 cm × 40 cm open box device, the bottom of the box was divided into 25 equal squares and the rats were quickly placed in the center of the box. Calculate the number of crossings in 5 minutes (horizontal motion score: the score of the four-claw into the
bottom square is 1 point) and the number of hind legs upright (vertical exercise score: the number of uprights, that is, the two front paws vacated off the ground or climbed the four walls as the scoring standard, 1 score 1 time).

2.7.3. Forced Swimming Test (FST). The test was carried out by placing the rat in a glass cylinder (46 cm high, 20 cm diameter) filled with 30 cm high water (25 ± 2°C). Two swim trainings were performed: an initial 15-minute pretest and then a 5-minute trial after 24 hours. As long as the mouse floats passively in the water and only makes a slight movement to keep its head above the waterline, it is considered to be stationary. What is more, we changed water between each test. The test session scored the immobile time by a qualified observer who turned a blind eye to treatment.

2.7.4. The Y-Maze Test. The Y-maze test is used as a measure of real-time spatial working memory to measure short-term memory. The Y-shaped labyrinth consists of three arms of equal angle (30 cm long × 5 cm wide × 12 cm high). Place the mouse at the end of one arm and allow it to move freely for 6 minutes in the maze. When the mouse’s hind paw is completely inside the arm, the arm is counted. Visually record a series of arm entries and calculate the percentage change. Spontaneous alternation is defined as the continuous entry into three arms, namely, ABC, CAB, or BCA but not CBC. The percentage is calculated as the ratio of actual alternation to possible alternation (de alternate% = [number of alternations/(total number of arms − 2)] × 100). The number of arm inlets is also used as an indicator of athletic activity.

2.8. Western Blot Assay. The frontal cortex and hippocampus were isolated from the rat brains and homogenized in lysis buffer (50 mm Tris–Cl, 150 mm NaCl, 0.02% NaN2, 100 μg/mL phenylmethylsulfonyl fluoride, 1 μg/mL aprotinin, and 1% Triton X-100) in the presence of a protease inhibitor and phosphatase inhibitor on ice. The lysate was centrifuged at 13,000 rpm for 10 min to obtain the supernatant. The protein concentrations were determined by the BCA protein assay kit. The lysed samples were separated by SDS-PAGE and then transferred to polyvinylidene fluoride (PVDF) membranes. After blocking with 5% skim milk for 2 h at room temperature, the membranes were incubated with specific primary antibodies at 4°C overnight. The PVDF membranes were then incubated with HRP-conjugated secondary antibodies for 2 h, and protein bands were captured via enhanced chemiluminescence. The gray intensity of the protein bands was analyzed by ImageJ software (NIH, Bethesda, MD).

2.9. RT-PCR. Total RNA was extracted and isolated from the hippocampus and cerebral cortex. Next, the concentration and purity of RNA were measured. Then, the high-quality total RNA was reverse transcribed. The primers of the target genes and GAPDH were used, as described as follows: BDNF: 5′-AGCTTGATCCGACCCCTCTCTG-3′ and R: 5′-CAGCAATCAGTTGTTCCGGC-3′; CREB: 5′-CTGA TTCCCAAAACGAA-3′ and R: 5′-CTGCCCACTGC TAGTTTGGT-3′; ERK: 5′-TACCGAGCCCAAGATCAT-3′ and R: 5′-GGAAGATAGGCGGTGGA-3′; and GAPDH: 5′-CCATGTGTGATGGTGTG-3′ and R: 5′-CCTTCACAATGCCAAGGT-3′. Real-time quantitative PCR analysis was performed with a SYBR® Premix Ex Taq. The relative expression levels of target genes were normalized against the level of GAPDH in the same cDNA by using the relative quantification method (2−ΔΔCT).

2.10. Statistical Analyses. Data were analyzed using the Statistical Program for the Social Sciences statistical software (SPSS 16.0, NY, USA). All data in the present study are expressed as the mean ± SEM. The data were first analyzed with Student’s t-test or one-way ANOVA, followed by Tukey’s post hoc test. A value of p < 0.05 was considered to be statistically significant for analysis.

3. Results

3.1. CSS and Coadministration of CSS and FLU Alleviate the Depressive Symptoms of Depression, Evasion, and Despair in CUMS Rats. After different interventions, compared with the control group, the sucrose preference index in the sucrose preference test (SPT) and the horizontal and vertical movements in the open field test (OFT) in the CUMS group were significantly decreased (p < 0.05), and the immobility time in the forced swimming test (FST) was significantly increased (p < 0.05). Compared with the CUMS group, the sucrose preference index and the horizontal and vertical movements of the different intervention groups were significantly increased (p < 0.05), and the immobility time was significantly decreased (p < 0.05), suggesting that CSS and coadministration of CSS and FLU both could alleviate the depressive symptoms of depression, evasion, and despair in CUMS rats. Among them, we can learn that high-dose CSS and CSS combined with fluoxetine can better alleviate depressive symptoms. In addition, we found that the sucrose preference index, the horizontal and vertical movements, and the immobility time of the coadministration of CSS and FLU were significantly better than CSS alone (p < 0.05) and fluoxetine alone (p < 0.05), suggesting that coadministration of CSS and FLU could better alleviate the depressive symptoms of depression, evasion, and despair in CUMS rats whether it is administered with CSS alone or fluoxetine alone (Figure 1).

3.2. CSS and Coadministration of CSS and FLU Improve Cognitive Function in CUMS Rats. After different interventions, there was no significant difference in the number of arm entries in the Y-maze test between the groups (p > 0.05), indicating that the percentage of spontaneous alternation in each group was not related to the change of exercise activity. Compared with the control group, the percentage of spontaneous alternation in the Y-maze test in the CUMS group was significantly decreased (p < 0.05). Compared with the CUMS group, the percentage of spontaneous alternation of the different intervention groups was significantly increased (p < 0.05), suggesting that CSS and coadministration of CSS and FLU both could improve...
Figure 1: CSS and coadministration of CSS and FLU improve depression, evasion, and despair in CUMS rats. The difference \( p < 0.05 \) was considered to be statistically significant. The syrup preference index of the sucrose preference test (SPT) (a). The immobility time of the forced swimming test (FST) (b). The horizontal movement (c) and vertical movement (d) of the open field test (OFT). Compared with the control group, \( \# p < 0.05 \); compared with the CUMS group, \( * p < 0.05 \); compared with the CSS group, \( \blacktriangle p < 0.05 \); compared with the FLU group, \( \blacksquare p < 0.05 \).
cognitive function in CUMS rats. Among them, we can see that high-dose CSS and CSS combined with fluoxetine can better improve the cognitive function. What is more, we found that the percentage of spontaneous alternation of the coadministration of CSS and FLU was significantly better than CSS alone (p < 0.05) and fluoxetine alone (p < 0.05), suggesting that coadministration of CSS and FLU could better improve cognitive function in CUMS rats whether it is administered with CSS alone or fluoxetine alone (Figure 2).

3.3. CSS and Coadministration of CSS and FLU Regulate the ERK-CREB-BDNF Signaling Pathway in the Hippocampus and Frontal Cortex. After different interventions, the expression of BDNF mRNA, CREB mRNA, ERK mRNA, BDNF, p-CREB/CREB, and p-ERK/ERK in the frontal cortex and hippocampus of the CUMS group were significantly lower than the control group (p < 0.01). Compared with the CUMS group, high-dose CSS and coadministration of high-dose CSS and FLU could increase the expression of BDNF, p-CREB/CREB, p-ERK/ERK, and BDNF mRNA, CREB mRNA, and ERK mRNA in the hippocampus and frontal cortex (p < 0.05). Low dose of CSS promoted the expression of BDNF mRNA, p-ERK/ERK, and ERK mRNA in the frontal cortex (p < 0.05) and the expression of BDNF, BDNF mRNA, p-CREB/CREB, CREB mRNA, p-ERK/ERK, and ERK mRNA in the hippocampus (p < 0.05). The coadministration of high-dose CSS and FLU promoted the expression of BDNF, p-ERK/ERK, BDNF mRNA, CREB mRNA, and ERK mRNA in the frontal cortex and hippocampus of the CUMS group (p < 0.05) and the expression of p-CREB/CREB in the hippocampus (p < 0.05). In addition, we found that the expression of BDNF mRNA, BDNF, p-CREB/CREB, CREB mRNA, p-ERK/ERK, and ERK mRNA in the frontal cortex of the coadministration of high dose of CSS and FLU was significantly better than CSS alone (p < 0.05) and fluoxetine alone (p < 0.05), suggesting that CSS can promote the expression of ERK mRNA, p-ERK/ERK, CREB mRNA, p-CREB/CREB, BDNF mRNA, and BDNF in the hippocampus and frontal cortex. CSS regulates the BDNF-ERK-CREB signaling pathway to play an antidepressant-like role, while the coadministration of CSS and FLU potentiates this regulation (Figures 3, 4, and 5).

4. Discussion

In this study, the CUMS rat model was used to study the antidepressant-like effects of CSS and fluoxetine. The depression-like behavior and cognitive function were evaluated by the sucrose preference test (SPT), forced swimming test (FST), open field test (OFT), and Y-maze test. What is more, the antidepressant mechanism of CSS and coadministration of CSS and FLU were studied through BDNF mRNA, ERK mRNA, CREB mRNA, BDNF, p-ERK/ERK, and p-
Many studies have found that mental illness often manifests as a significant cognitive impairment, and the assessment of cognitive function plays an important role in assessing mental illness [28, 29]. Chronic unpredictable mild stress (CUMS) is currently the most commonly used and most convincing rodent model of depression [30], and studies have shown that the CUMS program is a robust animal model of depression [31]. Depression-like behavior in rats can be reasonably inferred by using appropriate animal models and behavioral tests including the sucrose preference test (SPT), forced swimming test (FST), Y-maze test, and open field test [32]. Among them, the sucrose preference index in the sucrose preference test (SPT) was used to assess the loss of pleasure, the alternating percentage of the Y-maze test was used to assess the brain cognitive function, the forced time of the forced swimming test (FST) was used to evaluate the depression in animal models, and the horizontal and vertical movements in the open field test (OFT) was used to assess the animal evasion [33–35]. Our study found that CUMS can reduce the sucrose preference index, horizontal movement, vertical movement activity, and alternating percentage and increase the duration of immobility. In contrast, the sucrose preference index, horizontal movement, vertical movement, and percentage of alternation can be increased by the intervention of CSS; the duration of immobility, relieving depression, and cognitive dysfunction in rats can be reduced by it. The sucrose preference index, horizontal movement, vertical movement, alternating percentage, and immobility status of CSS combined with the fluoxetine group were better than their corresponding

Figure 3: CSS and coadministration of CSS and FLU improve the expression of BDNF mRNA and protein in the frontal cortex and hippocampus of CUMS rats. The difference $p < 0.05$ was considered to be statistically significant. BDNF mRNA in the frontal cortex (a) and hippocampus (c). BDNF protein expression in the frontal cortex (b) and hippocampus (d). Compared with the control group, $\# p < 0.05$; compared with the CUMS group, $^* p < 0.05$; compared with the CSS group, $▲ p < 0.05$; compared with the FLU group, $■ p < 0.05$. 

CREB/CREB levels in the rat hippocampus and frontal cortex by Western blot and RT-PCR.

Many studies have found that mental illness often manifests as a significant cognitive impairment, and the assessment of cognitive function plays an important role in assessing mental illness [28, 29]. Chronic unpredictable mild stress (CUMS) is currently the most commonly used and most convincing rodent model of depression [30], and studies have shown that the CUMS program is a robust animal model of depression [31]. Depression-like behavior in rats can be reasonably inferred by using appropriate animal models and behavioral tests including the sucrose preference test (SPT), forced swimming test (FST), Y-maze test, and open field test [32]. Among them, the sucrose preference index in the sucrose preference test (SPT) was used to assess the loss of pleasure, the alternating percentage of the Y-maze
CSS and fluoxetine groups. Among them, in each test, the combination treatment group was significantly better than the CSS group (p < 0.01), and the high-dose CSS combined with the fluoxetine group was significantly better than the fluoxetine group (p < 0.01). CSS and CSS combined with FLU improved the memory formation, despair, and pleasure of CUMS.

At present, considerable progress has been made in understanding the pathophysiology of severe depression, but there is still no model or mechanism that can be satisfactorily explained from all aspects [8]. In recent years, with the rapid development of neurophysiology and neuropathology, people gradually realize that depression is a complex physiological dysfunction caused by different reasons [36–38]. There are many hypotheses about the pathogenesis of depression, and neurotrophic factor deficiency is one of the most important hypotheses [39, 40]. BDNF can be expressed in various brain regions such as the cerebral cortex and hippocampus, which has biological functions to maintain synaptic growth as well as the growth, differentiation, and survival of neurons [41]. The BDNF transcription and regulation mechanisms are very complex as the multiple transcripts and complex transcriptional regulatory machinery [42]. A number of studies have demonstrated that BDNF preferentially binds to the TrkB receptor, and dysfunction of the BDNF/TrkB system is associated with the pathophysiology of brain diseases, including neurodegenerative diseases and mental illness [43–45]. In addition, various studies have shown that BDNF activates the MAPK cascade after binding to TrkB, of which the ERK pathway is one of the best characterized signal transduction pathways [46, 47]. The ERK pathway runs through the cell membrane and the nucleus, which effectively connects external signals with intracellular signals [48, 49]. CREB is a transcription factor and a downstream

**Figure 4:** CSS and coadministration of CSS and FLU improve the expression of ERK mRNA and p-ERK/ERK in the frontal cortex and hippocampus of CUMS rats. The difference p < 0.05 was considered to be statistically significant. ERK mRNA in the frontal cortex (a) and hippocampus (c). p-ERK/ERK in the frontal cortex (b) and hippocampus (d). Compared with the control group, *p < 0.05; compared with the CSS group, **p < 0.05; compared with the FLU group, ***p < 0.05.
target of ERK [50, 51]. A series of studies have revealed the important role of the BDNF-ERK-CREB signaling pathway in depression-like behavior and antidepressant effects. Recent clinical studies have shown that BDNF is a promising biomarker, and BDNF levels in serum of patients with depression are significantly reduced, while antidepressant treatment reverses this effect [52, 53]. Deleting BDNF in broad forebrain regions reduces the brain ability of learning and memory and greatly reduces the antidepressant ability of the antidepressant desipramine [54]. In a stressful environment, variant BDNF mice (BDNF (Met/Met)) showed anxiety, and this anxiety could not be reversed by fluoxetine [55]. Depletion of BDNF by transfection of lentiviral-derived shBDNF in the hippocampus inhibits the antidepressant effect of fluoxetine [56]. Chronic peripheral administration of BDNF can increase BDNF, p-ERK, and p-CREB levels in the hippocampus of mice, playing an antidepressant effect by directly increasing BDNF levels in the brain or activating TrkB-ERK-CREB signaling possibly [57–59]. Inhibitors of the ERK pathway include U0126 and specific MEK inhibitors. In order to provide direct evidence of the potential role of the ERK pathway in depression, mice were infused with U0126 infusion into the dorsal hippocampus (dHP) and prefrontal cortex (mPFC), after which the depressive symptoms including lack of pleasure and anxiety-like behavior appear [54]. In conclusion, these results indicate that BDNF is an important biomarker of depression and may exert antidepressant effects by activating ERK and CREB. Our data suggest that CSS can improve depression and cognitive function in CUMS rats and the coadministration of CSS and FLU enhances the antidepressant effects. CSS and coadministration of CSS and FLU may increase the level of CREB transcription and protein phosphorylation in the hippocampus.
and frontal cortex by increasing ERK transcription and protein phosphorylation in the hippocampus and frontal cortex, ultimately affecting BDNF transcriptional levels and increasing BDNF protein levels in the hippocampus and frontal cortex, which may regulate the ERK-CREB-BDNF pathway and play an antidepressant role as a result. In addition, CSS antidepressant effect is dose-dependent, and CSS has a dose-dependent effect on the transcription and expression of BDNF and CREB.

Besides, our results found that the coadministration of high dose of CSS and FLU is superior to high-dose CSS or fluoxetine in improving the depressive symptoms and cognitive function of CUMS rats. Previous studies have found that CSS can affect the pharmacokinetics of fluoxetine [60]. However, the mechanism of this enhancement is still unknown and the underlying mechanism needs further investigation.

5. Conclusions

Taken together, we found that both CSS and coadministration of CSS and FLU can relieve and improve the depression-like behavior and cognitive function, which may be due to the regulation of the BDNF/ERK/CREB signaling pathway in the hippocampus and frontal cortex. Among them, the coadministration of CSS and FLU can enhance the antidepressant effect of CSS or FLU alone, and there may be the drug interaction between CSS and FLU. The underlying mechanism needs further investigation.

Data Availability

The data used to support the findings of this study are available from the corresponding authors upon request.

Conflicts of Interest

The authors declare no conflicts of interest.

Authors’ Contributions

LY, XX, ZH, XQ, and HH contributed the conception and the design of this study. LY, XX, and ZH conducted the experiments. LY, SW, ZL, DW, ZG, and QJ wrote the main manuscript text. All the authors participated in performing the laboratory analyses and interpreting the data. XQ supervised the whole study. Lijing Yan and Xia Xu contributed equally to this work. All the listed authors have read and approved the submitted manuscript.

Acknowledgments

The study was supported by the Youth Foundation of National Natural Science Foundation of China (Grant No. 81202807 to Xinjian Qiu, Grant No. 81703963 to Linlin Zhao), the Foundation of National Natural Science Foundation of Hunan (Grant No. 2018JJ2667 to Xinjian Qiu), the China Postdoctoral Science Foundation (Grant No. 2015M572254 to Xinjian Qiu), the Scientific Research Project of Chinese Traditional Medicine Administration Bureau in Hunan Province (Grant No. 201806 to Xinjian Qiu), and the Prominent Traditional Chinese Medicine Doctor Suiyu Hu’s Inheritance Studio.

References

[1] L. E. Schwartz, K. H. Howell, and L. E. Jamison, “Effect of time since loss on grief, resilience, and depression among bereaved emerging adults,” Death studies, vol. 42, no. 9, pp. 537–547, 2018.
[2] C. N. Yohn, M. M. Gergues, and B. A. Samuels, “The role of 5-HT receptors in depression,” Molecular Brain, vol. 10, no. 1, p. 28, 2017.
[3] A. Ribeiro, J. P. Ribeiro, and O. von Doellinger, “Depression and psychodynamic psychotherapy,” Revista Brasileira de Psiquiatria, vol. 40, no. 1, pp. 105–109, 2018.
[4] Y. I. Nillni, A. K. Wesselink, J. L. Gradus et al., “Depression, anxiety, and psychotropic medication use and fecundability,” American Journal of Obstetrics and Gynecology, vol. 215, no. 4, pp. 453.e1–453.e8, 2016.
[5] S. R. Zubrick, J. Hafekost, M. G. Sawyer, G. Patton, and D. Lawrence, “The continuity and duration of depression and its relationship to non-suicidal self-harm and suicidal ideation and behavior in adolescents 12–17,” Journal of Affective Disorders, vol. 220, pp. 49–56, 2017.
[6] S. D. Boone and A. M. Brausch, “Physical activity, exercise motivations, depression, and nonsuicidal self-injury in youth,” Suicide and Life-Threatening Behavior, vol. 46, no. 5, pp. 625–633, 2016.
[7] C. R. Hsieh and X. Qin, “Depression hurts, depression costs: the medical spending attributable to depression and depressive symptoms in China,” Health Economics, vol. 27, no. 3, pp. 525–544, 2018.
[8] G. S. Malhi and J. J. Mann, “Depression,” Lancet, vol. 392, no. 10161, pp. 2299–2312, 2018.
[9] D. J. David and D. Gourion, “Antidepressant and tolerance: determinants and management of major side effects,” L’Encéphale, vol. 42, no. 6, pp. 553–561, 2016.
[10] C. Moret, M. Isaac, and M. Briley, “Problems associated with long-term treatment with selective serotonin reuptake inhibitors,” Journal of Psychopharmacology, vol. 23, no. 8, pp. 967–974, 2009.
[11] J. Qiu, S. Y. Hu, G. Q. Shi, and S. E. Wang, “Changes in regional cerebral blood flow with Chaihu-Shugan-San in the treatment of major depression,” Pharmacognosy Magazine, vol. 10, no. 40, pp. 503–508, 2014.
[12] S. Peretti, R. Judge, and I. Hindmarch, “Safety and tolerability considerations: tricyclic antidepressants vs. selective serotonin reuptake inhibitors,” Acta Psychiatrica Scandinavica, vol. 101, no. 5, pp. 17–25, 2000.
[13] J. Qiu, S.-Y. Hu, C.-H. Zhang, G.-Q. Shi, S.-E. Wang, and T. Xiang, “The effect of Chaihu-Shugan-San and its components on the expression of ERK5 in the hippocampus of depressed rats,” Journal of Ethnopharmacology, vol. 152, no. 2, pp. 320–326, 2014.
[14] G. Lee and H. Bae, “Therapeutic effects of phytochemicals and medicinal herbs on depression,” BioMed Research International, vol. 2017, Article ID 6596241, 11 pages, 2017.
[15] D. Picking, N. Younger, S. Mitchell, and R. Delgoda, “The prevalence of herbal medicine home use and concomitant
use with pharmaceutical medicines in Jamaica,” *Journal of Ethnopharmacology*, vol. 137, no. 1, pp. 305–311, 2011.

[16] Z. Yue, L. I. Yong-Xiang, L. Keng, Y. Qian, and X. Zhang, “Effect of Chaihu-shugan-san combined with fluoxetine on IL-6, IL-1β, TNF-α in postpartum depression,” *Chinese Journal of Biochemical and Pharmacaceutics*, vol. 36, no. 4, pp. 127–129, 2016.

[17] W.-F. Yeung, K.-F. Chung, K.-Y. Ng et al., “Prescription of Chinese herbal medicine in pattern-based traditional Chinese medicine treatment for depression: a systematic review,” *Evidence-based Complementary and Alternative Medicine*, vol. 2015, Article ID 160189, 12 pages, 2015.

[18] Y. Sun, X. Xu, J. Zhang, and Y. Chen, “Treatment of depression with Chai Hu Shu Gan San: a systematic review and meta-analysis of 42 randomized controlled trials,” *BMC Complementary and Alternative Medicine*, vol. 18, no. 1, p. 66, 2018.

[19] Y. Wang, R. Fan, and X. Huang, “Meta-analysis of the clinical effectiveness of traditional Chinese formula Chaihu-Shugan-San in depression,” *Journal of Ethnopharmacology*, vol. 141, no. 2, pp. 571–577, 2012.

[20] Q. H. Yang, Y. J. Xu, G. F. Feng et al., “p38 Mapk signal pathway involved in anti-inflammatory effect of chaihu-shugan-san and shen-ling-bai-zhu-san on hepatocyte in non-alcoholic steatohepatitis rats,” *African Journal of Traditional, Complementary, and Alternative Medicine*, vol. 11, no. 1, pp. 213–221, 2013.

[21] Y. Liang, Y. Zhang, Y. Deng et al., “Chaihu-Shugan-San decoction modulates intestinal microbe dysbiosis and alleviates chronic metabolic inflammation in NAFLD rats via the NLRP3 inflammasome pathway,” *Evidence-based Complementary and Alternative Medicine*, vol. 2018, Article ID 9390786, 11 pages, 2018.

[22] Y. H. Li, C. H. Zhang, S. E. Wang, J. Qiu, S. Y. Hu, and G. L. Xiao, “Effects of Chaihu Shugan San on behavior and plasma levels of corticotropin releasing hormone and adrenocorticotropic hormone of rats with chronic mild unpredicted stress depression,” *Journal of Chinese Integrative Medicine*, vol. 7, no. 11, pp. 1073–1077, 2009.

[23] Y. H. Li, C. H. Zhang, J. Qiu et al., “Antidepressant-like effects of Chaihu-Shugan-San via SAPK/JNK signal transduction in rat models of depression,” *Pharmacognosy Magazine*, vol. 10, no. 39, pp. 271–277, 2014.

[24] S. Wang, S. Hu, C. Zhang, J. Qiu, and Y. Li, “Effect of Chaihu Shugan San and its components on expression of ERK1/2 mRNA in the hippocampus of rats with chronic mild unpredicted stress depression,” *Journal of Central South University Medical Sciences*, vol. 36, no. 2, pp. 93–100, 2011.

[25] D. Ying, Z. Chun-Hu, and Z. Hai-Nan, “Effects of Chaihu Shugan powder on the behavior and expressions of BDNF and TrkB in the hippocampus, amygdala, and the frontal lobe in rat model of depression,” *Chinese journal of integrated traditional and Western medicine*, vol. 31, no. 10, pp. 1373–1378, 2011.

[26] J. Jung, K. Loy, E. M. Schilling et al., “The antidepressant fluoxetine mobilizes vesicles to the recycling pool of rat hippocampal synapses during high activity,” *Molecular Neurobiology*, vol. 49, no. 2, pp. 916–930, 2014.

[27] H. Sharifi, A. Nayebi, S. Farajinia, and R. Haddadi, “Effect of buspirone, fluoxetine and 8-OH-DPAT on striatal expression of Bax, caspase-3 and Bcl-2 proteins in 6-hydroxydopamine-induced hemi-Parkinsonian rats,” *Advanced Pharmaceutical Bulletin*, vol. 5, no. 4, pp. 491–495, 2015.

[28] S. Potvin, G. Charbonneau, R. P. Juster, S. Purdon, and S. V. Tourjman, “Self-evaluation and objective assessment of cognition in major depression and attention deficit disorder: implications for clinical practice,” *Comprehensive Psychiatry*, vol. 70, pp. 53–64, 2016.

[29] C. V. Ott, A. J. Bjertrup, J. H. Jensen et al., “Screening for cognitive dysfunction in unipolar depression: validation and evaluation of objective and subjective tools,” *Journal of Affective Disorders*, vol. 190, pp. 607–615, 2016.

[30] H. Qiao, M.-X. Li, C. Xu, H.-B. Chen, S.-C. An, and X.-M. Ma, “Dendritic spines in depression: what we learned from animal models,” *Neural Plasticity*, vol. 2016, Article ID 8056370, 26 pages, 2016.

[31] S. Antoniuk, M. Bajta, E. Ponimaskin, and J. Włodarczyk, “Chronic unpredictable mild stress for modeling depression in rodents: Meta-analysis of model reliability,” *Neuroscience & Biobehavioral Reviews*, vol. 99, pp. 101–116, 2019.

[32] D. H. Overstreet, “Modeling depression in animal models,” *Methods in Molecular Biology*, vol. 829, no. 1, pp. 125–144, 2012.

[33] C. Hu, Y. Luo, H. Wang et al., “Re-evaluation of the interrelationships among the behavioral tests in rats exposed to chronic unpredictable mild stress,” *PLOS ONE*, vol. 12, no. 9, p. e0185129, 2017.

[34] H. M. Abelaira, G. Z. Reus, and J. Quevedo, “Animal models as tools to study the pathophysiology of depression,” *Revista Brasileira de Psiquiatria*, vol. 35, suppl 2, pp. S112–S120, 2013.

[35] A. P. West, “Neurobehavioral studies of forced swimming: the role of learning and memory in the forced swim test,” *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, vol. 14, no. 6, pp. 863–874, 1990.

[36] J. Leszek, E. Trypka, E. Koutsouraki et al., “Late-life depression and Alzheimer disease: a potential synergy of the underlying mechanisms,” *Current Medicinal Chemistry*, vol. 25, no. 39, p. 5389, 2019.

[37] E. Palazidou, “The neurobiology of depression,” *British Medical Bulletin*, vol. 101, no. 1, pp. 127–145, 2012.

[38] S. J. Claes, “Stress and depression: clinical, neurobiological and genetic perspectives,” *Tijdschrift voor Psychiatrie*, vol. 51, no. 8, pp. 551–557, 2009.

[39] S. Jha, B. E. Dong, Y. Xue, D. F. Delotterie, M. G. Vail, and K. Sakata, “Antidepressive and BDNF effects of enriched environment treatment across ages in mice lacking BDNF expression through promoter IV,” *Translational Psychiatry*, vol. 6, no. 9, p. e896, 2016.

[40] B. E. Dong, Y. Xue, and K. Sakata, “The effect of enriched environment across ages: a study of anhedonia and BDNF gene induction,” *Genes, Brain and Behavior*, vol. 17, no. 8, p. e12485, 2018.

[41] I. Zaletel, D. Filipović, and N. Puškaš, “Hippocampal BDNF in physiological conditions and social isolation,” *Reviews in the Neurosciences*, vol. 28, no. 6, 2017.

[42] V. Begni, M. A. Riva, and A. Cattaneo, “Cellular and molecular mechanisms of the brain-derived neurotrophic factor in physiological and pathological conditions,” *Clinical Science*, vol. 131, no. 2, pp. 123–138, 2017.

[43] T. Numakawa, H. Odaka, and N. Adachi, “Actions of brain-derived neurotrophin factor in the neurogenesis and neuronal function, and its involvement in the pathophysiology of brain
diseases,” International Journal of Molecular Sciences, vol. 19, no. 11, p. 3650, 2018.

[44] T. Numakawa, S. Suzuki, E. Kumamaru, N. Adachi, M. Richards, and H. Kunugi, “BDNF function and intracellular signaling in neurons,” Histology and Histopathology, vol. 25, no. 2, pp. 237–258, 2010.

[45] K. Cowansage, J. LeDoux, and M. H. Monfils, “Brain-derived neurotrophic factor: a dynamic gatekeeper of neural plasticity,” Current Molecular Pharmacology, vol. 3, no. 1, pp. 12–29, 2010.

[46] J. D. Sweatt, “Mitogen-activated protein kinases in synaptic plasticity and memory,” Current Opinion in Neurobiology, vol. 14, no. 3, pp. 311–317, 2004.

[47] G. Leal, D. Comprido, and C. B. Duarte, “BDNF-induced local protein synthesis and synaptic plasticity,” Neuropharmacology, vol. 76, pp. 639–656, 2014.

[48] J. Q. Wang and L. Mao, “The ERK Pathway: molecular mechanisms and treatment of depression,” Molecular Neurobiology, vol. 56, no. 9, pp. 6197–6205, 2019.

[49] X. Qi, W. Lin, D. Wang, Y. Pan, W. Wang, and M. Sun, “A role for the extracellular signal-regulated kinase signal pathway in depressive-like behavior,” Behavioural Brain Research, vol. 199, no. 2, pp. 203–209, 2009.

[50] J. Xing, D. D. Ginty, and M. E. Greenberg, “Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase,” Science, vol. 273, no. 5277, pp. 959–963, 1996.

[51] L. Guan, N. Jia, X. Zhao et al., “The involvement of ERK/CREB/Bcl-2 in depression-like behavior in prenatally stressed offspring rats,” Brain Research Bulletin, vol. 99, no. 5, pp. 1–8, 2013.

[52] M. F. Grunebaum, S. P. Ellis, J. G. Keilp et al., “Ketamine versus midazolam in bipolar depression with suicidal thoughts: a pilot midazolam-controlled randomized clinical trial,” Bipolar Disorders, vol. 19, no. 3, pp. 176–183, 2017.

[53] C. W. Carspecken, A. Borisovskaya, S. T. Lan et al., “Ketamine anesthesia does not improve depression scores in electroconvulsive therapy,” Journal of Neurosurgical Anesthesiology, vol. 30, no. 4, pp. 305–313, 2018.

[54] H. J. Jin, L. Pei, Y. N. Li et al., “Alleviative effects of fluoxetine on depressive-like behaviors by epigenetic regulation of BDNF gene transcription in mouse model of post-stroke depression,” Science, vol. 314, no. 5796, pp. 140–143, 2006.

[55] H. D. Schmidt and R. S. Duman, “Peripheral BDNF produces antidepressant-like effects in cellular and behavioral models,” Neuropsychopharmacology, vol. 35, no. 12, pp. 2378–2391, 2010.

[56] J. A. Siuciak, D. R. Lewis, S. J. Wiegand, and R. M. Lindsay, “Antidepressant-like effect of brain-derived neurotrophic factor (BDNF),” Pharmacology Biochemistry & Behavior, vol. 56, no. 1, pp. 131–137, 1997.

[57] R. W. Sirianni, P. Olausson, A. S. Chiu, J. R. Taylor, and W. M. Saltzman, “The behavioral and biochemical effects of BDNF containing polymers implanted in the hippocampus of rats,” Brain Research, vol. 1321, pp. 40–50, 2010.

[58] L. Yan, S. Wang, L. Zhao et al., “The herb-drug pharmacokinetic interaction of fluoxetine and its metabolite norfluoxetine with a traditional Chinese medicine in rats by LC-MS/MS,” Evidence-Based Complementary and Alternative Medicine, vol. 2019, Article ID 2471870, 11 pages, 2019.